Eisai Inc., the U.S. operation of Tokyo-based Eisai Co., Ltd., has entered into an agreement with Arena Pharmaceuticals for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential treatment of obesity, including weight loss. If approved, Eisai will market and distribute lorcaserin in the U.S. Arena will manufacture and supply the finished commercial product at its facility in Switzerland. “As part of our human health care mission, Eisai is committed to increasing ben...